Targeted Oncology published an Investigator Perspectives video series featuring three experts discussing clinical considerations for ROS1-positive advanced NSCLC, RNA-based sequencing, treatment selection, and ROS1 results after treatment.
Public source
Publisher name
Public post
Three experts. One evolving question: How should we approach ROS1-positive advanced NSCLC today? In the latest Investigator Perspectives video series, Ticiana Leal, MD,…
Company
Targeted Oncology
The Community Resource in Targeted Therapies
- Industry
- Online Audio and Video Media
- Location
- Cranbury Township, US
- Company size
- 201–500 employees
About Targeted Oncology
TargetedOnc.com provides content focused on next generation therapeutics and their molecular targets. As the field of oncology continues to trend toward systemic biology and molecular aberrations, the challenge facing many oncologists is staying recent and up-to-date with the future of cancer therapeutics. TargetedOnc.com focuses on the next stage of cancer development, focusing on cutting edge therapies and their biological targets. Content is organized by therapy type, target, peer-reviewed content, and conference coverage.
See moreLatest activity
Latest activity from Targeted Oncology
6 signals
Presence & Recognition
Targeted Oncology hosted an episode of Targeted Talks discussing changes to radiation oncology billing in 2026 and their implications for practices and providers nationwide.
Research & Knowledge
Targeted Oncology published new phase 1/2 data in The New England Journal of Medicine showing daraxonrasib produced meaningful responses in previously treated RAS-mutant non-small cell lung cancer in the RMC-6236-001 trial.
Presence & Recognition
Targeted Oncology released a new episode of Targeted Talks featuring gynecologic oncologist Noelle Cloven discussing Gynecologic Cancer Awareness Month and shifting incidence rates in the field.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
International Association for the Study of Lung Cancer
International Association for the Study of Lung Cancer published an episode titled LungCancerConsidered discussing the evolving management of oligometastatic lung cancer, including patient selection, consolidative therapies, and ctDNA guidance.
Research & Knowledge
OncologyTube.com
OncologyTube.com reports that Truqap plus abiraterone for PTEN-deficient mHSPC after CAPItello-281 showed a median recurrence-free survival of 33.2 months versus 25.7 months.
Research & Knowledge
OncoAlert
OncoAlert published a new Oncology Newsletter highlighting Daraxonrasib in previously treated RAS-mutant NSCLC with promising response rates and important toxicity considerations.
Research & Knowledge
iOMEDICO
iOMEDICO published the final results of the REALTRK registry on rare NTRK fusion-positive cancers in JCO Precision Oncology, including 47 adults with advanced solid tumors and 26 patients who received TRK inhibitor therapy.
Research & Knowledge
Aptitude Health